A Lesson to Learn o...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$78.80 0.05 | 0.06%
06/18/13 - 04:00 PM ET
1.97M / 2.48M
Vol / Avg. Vol:79.08 / 78.75
Open / Prev. Close:77.45 - 79.59
Today's Range:38.44 - 87.47
52 Wk Range:91.67%
Performance YTD:TheStreet Rating:
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- Worth Repeating: Vertex Is the Next Gilead Sciences 04.19.13 | 08:04 am
- Futures Point Higher; Boston Manhunt Plays Out
04.19.13 | 08:04 am - The New #38 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals 04.10.13 | 04:04 pm
- Analysts' Actions: JNJ FNFG WLL CA VRTX 04.08.13 | 08:04 am
- Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR 04.03.13 | 06:04 am
- Cramer's 'Mad Money' Recap: The Winning Formula 04.02.13 | 08:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 3 Stocks Pushing The Drugs Industry Higher 03.08.13 | 12:03 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Winner 03.06.13 | 05:03 pm
- Vertex Pharmaceuticals Stock Sell Recommendation Reiterated (VRTX) 03.04.13 | 09:03 am
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- Market Close Report: NASDAQ Composite index closes at 3,469.22 up 45.17 points - NASDAQ 06.07.13 | 08:06 pm
- Mid-Afternoon Market Update: Markets Cool Off Slightly, Vertex Rises - Benzinga 06.07.13 | 03:06 pm
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Inside Wall Street: closer to a cystic fibrosis cure - MSN Money 05.03.13 | 01:05 pm
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Results - Investor's Business Daily 05.02.13 | 06:05 pm
- Stocks Down In Rising Trade; Nuance Communications Falls - Investor's Business Daily 04.30.13 | 10:04 am
- Vertex Pharmaceuticals Earnings: Here’s Why Shares are Up Now - Wall St. Cheat Sheet 04.30.13 | 06:04 am
- Vertex Pharmaceuticals Incorporated Earnings Preview: Can This Streak Finally End? - Wall St. Cheat Sheet 04.29.13 | 11:04 am
- Weekly Preview: Focus Shifts from Earnings to Economy - Benzinga 04.26.13 | 04:04 pm
